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article under the CC BY-NC-ND licenseAbstract Objective: This study was undertaken to determine the likelihood of having serum
total prostate specific antigen (PSA) levels 4.0 ng/mL and 10.0 ng/mL among a cohort of
non-obese and obese Nigerian men with lower urinary tract symptoms (LUTS).
Methods: This was a prospective cross-sectional survey among men who presented with benign
prostatic hypertrophy to the urology clinic of the Ekiti State University Teaching Hospital, Ado
-Ekiti with LUTS between January 1 and December 31, 2014. One hundred and forty men who
presented in the urologic clinic with LUTS were recruited. PSA was analyzed using standard
method while other clinical variables were collected using a clinical case form. Multivariate
logistic regression was used to estimate the odds of an abnormal PSA of 4.0 ng/mL or
10.0 ng/mL in these men.
Results: The mean ages of obese and non-obese men were 64.8 and 64.0 years respectively.
The mean total serum PSA were 14.8 and 13.2 ng/mL for obese and non-obese men respec-
tively. Univariate analysis showed no difference (p > 0.05) in the proportion of obese and
non-obese men with LUTS who had a PSA threshold of at least 4.0 ng/mL. Multivariate logistic
regression showed that, at a PSA threshold of 10.0 ng/mL, obese men had a statistically signif-
icant proportion (p < 0.05). Although not significant, non-obese patients were less likely to
have PSA level of 4.0 ng/mL (OR 0.701; 95% CI 0.301e1.630) compared to obese men. Inhoo.com (P.T. Adegun).
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Obesity-related PSA level in Nigerian men 159the same vein, non-obese men were less likely to have a PSA level of 10.0 ng/mL (OR, 0.686;
95% CI, 0.318e1.478) in a simultaneous context of age.
Conclusion: Our study demonstrated that, in a sample population of predominantly native Af-
rican men, there was a non-significantly higher likelihood of overweight/obese patients having
a higher serum PSA level than the non-obese. A community based study is needed to further
confirm this finding.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate specific antigen (PSA) was reported to have been
first identified by researchers attempting to find a sub-
stance in seminal fluid that would aid in the investigation of
rape cases [1]. It was subsequently found to be able to
identify prostate cancer (PCa) in men not known to have
the cancer [2]. Men with PCa generally have elevated PSA
levels in their serum; this tumour marker is now frequently
used for PCa screening, diagnosis and monitoring of
response to therapy [3e8].
To improve treatment outcome, PSA has been developed
which categorized patients into three; viz: (i) low risk
disease (LRD), (ii) intermediate risk disease (IRD), and (iii)
high risk disease (HRD) especially when combined with
Gleason score and American Joint Commission on Cancer
clinical tumour category so as to determine the outcome
and suitability of various treatment modalities for PCa [9].
In such instances PSA level of <10.0 ng/mL was matched for
LRD, PSA level of 10.0e20.0 ng/mL was matched for IRD
while PSA of >20.0 ng/mL was matched for HRD [9]. The
low specificity of PSA testing and questionable benefits of
PSA screening on PCa mortality highlight the need for bet-
ter detection strategies for PCa [10].
Some studies suggested that body weight (BW) and body
mass index (BMI) have effect on serum PSA, while some
other researchers hold contrary opinion [5e8,11]. The
variation of PSA levels with obesity in contemporary times
poses a great challenge in the utilization of the marker for
diagnosis. Establishing the relationship between PSA levels
and obesity will detect the influence of BMI in the inter-
pretation and clinical evaluation of PSA results. Moreover,
PSA levels differ between various ethnic groups and races
[12]. It is uncertain whether findings from studies investi-
gating the association between BMI and PSA conducted
primarily in Western populations can be applied to other
ethnic groups.
In our country where healthcare infrastructure is over-
stretched coupled with a rising prevalence of cardiovascu-
lar risk including obesity, knowledge of the influence of
concomitant co-morbidities such as obesity on serum PSA
concentrations may improve the discriminant value of this
test for predicting PCa and reduce the number of unnec-
essary biopsies and subsequent over-diagnosis of indolent
cancers. In this study we examined the likelihood of having
a serum PSA of 4.0 ng/mL and 10.0 ng/mL in obese and
non-obese Nigerian men presenting with lower urinary tract
symptoms (LUTS).2. Patients and methods
2.1. Study site
This was a prospective hospital based cross-sectional
observational study conducted at the urology clinic of
Ekiti State University Teaching Hospital (EKSUTH), Ado-
Ekiti, South-Western Nigeria. The study covered a period
between 1st January and 31st December, 2014.
2.2. Subject’s selection
One hundred and forty consecutive patients aged 40 years
and above, who presented to urology clinic with LUTS
within the study period were recruited.
However, the following categories of patients were
excluded:
(i) those who have had digital rectal examination (DRE);
(ii) those who have had sexual intercourse within 24 h of
examination;
(iii) those who have had recent catheterization or any
other form of urologic manipulations;
(iv) those on 5-a-reductase inhibitor;
(v) those with a diagnosis of PCa;
(vi) those who have had prostate surgery or prostatitis;
(vii) those who did not give their consent;
(viii) All patients who had suspicious DRE or had PSA of
10.0 ng/mL were subjected to prostate biopsy and
were excluded if positive for cancer.2.3. Ethical consideration
This study was approved by the Health Research and Ethics
Committee of EKSUTH. All the participants were
adequately informed through written notice before the
data were collected.
2.4. Data collection
2.4.1. Anthropometric variable
Height without shoes was measured to the nearest centi-
metre with a stadiometer (seca, Birmingham, UK) and
weight in light clothing was measured to the nearest 0.1 kg,
with a bathroom scale (Zhongshan Camry Electronic,
Guangdong, China). BMI was calculated as a ratio of weight
160 P.T. Adegun et al.(kg) to height squared (m2). All anthropometric measure-
ments were made by trained observers. The subjects were
then classified as non-obese (BMI <25 kg/m2) or obese [BMI
25 kg/m2] according to Asian-Pacific classification more
suited for African community [13].
2.4.2. PSA assay
Normal laboratory procedures were complied with in car-
rying out PSA analysis. About 5 mL of blood sample was
taken into the screwed cap plain specimen bottle for the
laboratory analysis of PSA. The blood sample was left to
retract for about 30 min. Each set of sample was centri-
fuged at 2500 g for 5 min after which serum was separated
into another screwed cap plain specimen bottle. The serum
was later kept frozen till analysis of that batch. Serum PSA
was determined using ready-to-use enzyme immunoassay
commercially manufactured kit (Teco Diagnostic Labora-
tory, USA). This was based on the principle that PSA
molecule was sandwiched between solid phase (rabbit anti-
PSA antibody) and enzyme linked antibodies (monoclonal
anti-PSA conjugated to Horse raddish peroxidise) [14].
2.5. Statistical analysis
The mean and standard deviation were used as appropriate
to describe normally distributed continuous data. Median
and inter-quartile (IQ) ranges and ManneWhitney U-test
were employed in analysing between group differences for
skewed variables. A p-value was calculated using the in-
dependent t-test for continuous variables and the Pearson
Chi-square test for categorical variables. Two separate PSA
thresholds, 4.0 and 10.0 ng/mL, were used to categorize
PSA values as “normal” or “abnormal” for the analyses. To
describe the association between age, obesity and the
likelihood of a certain serum total PSA level, multivariate
analysis was used after dichotomising men as having a PSATable 1 The demographic and clinical characteristics of patien
Parameters Non-obese (N Z36)
Age (mean  SD), year 64.00  11.26
Marital status, n(%)
Single 2(5.6)
Married 34(94.4)
Occupation, n(%)
Public servant 8(22.2)
Business 13(36.1)
Retired 7(19.5)
Others 8(22.2)
Comorbidity, n(%)
Hypertension 10(27.8)
Diabetes 3(8.3)
Alcohol 18(50.0)
BMI (mean  SD), kg/m2 22.62  2.28
IPSS score 2.22  0.76
Bother’s score 3.92  0.28
PSA (median, IQ range), ng/mL 13.2, 160.2
PSA 4.0 ng/mL, n(%) 25(69.4)
PSA 10.0 ng/mL, n(%) 19(52.8)
95% IC, 95% confidential interval; IQ, inter-quartile; LUTS, lower urin
deviation.level 4.0 or 10.0 ng/mL, respectively. The odds ratio
(OR) of having an ‘abnormal’ PSA level for each threshold
was then calculated, using overweight/obese men as the
reference. The OR of having normal or abnormal PSA was
also dichotomised between ages 65 years and <65 years
with 65 years as the reference. The SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA) was used for the statistical
analyses and p < 0.05 was considered statistically signifi-
cant for all analyses.
3. Results
Table 1 shows the demographic characteristics of patients
with LUTS. The mean ages of overweight/obese and non-
obese men with LUTS were 64.00  11.26 and
64.80  10.88 years respectively. There was no statistical
difference between the mean ages (p > 0.05). The median
(IQ range) of the PSA level was 13.2(160.2) ng/mL for non-
obese patients and 14.8(145.1) ng/mL for overweight/
obese group. The number of overweight/obese patients
with PSA level 10 ng/mL was 64(61.5%) while 19(52.8%)
non-obese patients had PSA 10.0 ng/mL. This was not
statistically significant even though greater proportion of
obese patients had PSA 10 ng/mL.
Table 2 shows the multivariate logistic regression anal-
ysis of the relationship between age and BMI on serum PSA
threshold of 4.0 ng/mL and 10.0 ng/mL.
Although there was no statistically significant difference,
non-obese patients were less likely to have PSA level of
4.0 ng/mL (0.701) as shown in Model 1. Also, Model 1 shows
that patients aged<65 years were 1.395 times likely to have
a PSA 4.0 ng/mL compared to older patients. This finding
was also not statistically significant. Model 2 shows that
patients aged <65 years were less likely to have a PSA value
of 10.0 ng/mL compared with older patients, while non-
obese patients were less likely to have a PSA 10.0 ng/mL.ts with LUTS.
Overweight/Obese (N Z104) p-Value
64.80  10.88 0.708
5(4.8) 0.895
99(95.2)
38(36.5) 0.104
20(19.2)
29(27.9)
17(16.4)
35(33.6) 0.292
14(13.5) 0.417
55(52.9) 0.765
28.59  2.40 <0.001
2.19  0.66 0.107
3.85  0.58 0.182
14.8, 145.1 0.334
79(76.0) 0.441
64(61.5) 0.359
ary tract symptoms; PSA, prostate specific antigen; SD, standard
Table 2 Multivariate logistic regression showing predictors of PSA values of 4.0 ng/mL and 10.0 ng/mL.
Variables B coeff SE OR 95% CI p-Value
Model 1 (PSA 4.0 ng/mL)
BMI (reference is overweight/obesity) 0.356 0.431 0.701 0.301e1.630 0.409
Age (reference is age 65 years) 0.333 390 1.395 0.649e2.995 0.394
Model 2 (PSA 10.0 ng/mL)
BMI (reference is overweight/obesity) 0.377 0.392 0.686 0.318e1.478 0.336
Age (reference is age 65 years) 0.233 0.248 0.792 0.400e1.567 0.502
B coeff, B coefficient; SE, standard error; OR, odd ratio; 95% CI, 95% confidential interval; BMI, body mass index; PSA, prostate specific
antigen.
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Having a serum PSA level of above 10.0 ng/mL has been
associated with increasing risk of PCa and this has driven
the increase in the use of PSA as screening marker for PCa
[10]. We sought to establish the effect of obesity on
the likelihood of having serum PSA of 4.0 ng/mL (normal
0e4.0 ng/mL and indicative of PCa 10.0 ng/mL)
among Nigerian men with LUTS. When PSA thresholds of
4.0 ng/mL and 10.0 ng/mL were compared between
non-obese and overweight/obese, we found that PSA
threshold of 4.0 ng/mL and 10.0 ng/mL were prevalent
among overweight/obese patients. Although this difference
did not reach statistical significance.
Our multivariate logistic analysis showed a non-
statistically significant trend towards a higher likelihood
of overweight/obese men having a total serum PSA level
4.0 ng/mL and 10.0 ng/mL. When this threshold was
considered, a trend of increasing PSA level with increasing
BMI was noted. This is similar to the findings of Loeb et al.
[15] who found that total PSA increased with an increasing
BMI in a cohort of nearly 600 men who underwent radical
prostatectomy (RP) by a single surgeon [15].
Besides, when our threshold was considered, a trend of
decreasing PSA level with increasing BMI could not be
established. This finding is contrary to that of Curp and
Porter [16] and some researchers who found a decreasing
level of point estimates of abnormal PSA level with
increasing BMI although the authors’ studies were better
powered. However, most of these studies were amongst
men of cross-cultural origins, ranging from Hispanics to
Koreans [17e19]. In spite of this, Naito et al. [20] found
that there was an increased serum PSA with Japanese men
with higher normal BMI even though they also reported a
lower PSA among the overweight/obese. Although the
exact mechanism for lower PSA has not been fully eluci-
dated, their findings were based on the theory of hormonal
hypothesis that suggested a possible interaction between
body adiposity and steroid hormone metabolism [19]. Other
contributory postulation is that, men with a higher BMI
could have larger plasma volumes, which could decrease
serum concentrations of soluble tumour markers [21]. All
the above postulations are still subject of debate.
Moreover, it should be noted that PSA levels are influ-
enced by a number of demographic, lifestyle, and health
characteristics, all of which deserve careful attention in
the interpretation of test results [22]. The association be-
tween BMI and PSA may vary according to populationcharacteristics [12,23], and this may explain why this study
is different from those conducted outside Africa. There-
fore, the explanation for the finding in this study may be
due to racial differences as a result of larger prostate size
and higher mean PSA typical of the African race compared
to others [24]. However, our study is hospital based and less
powered. Therefore, additional studies are needed to
further clarify the relationships between BMI and PSA and
determine whether weight reduction could lead to
improved outcomes.
Our findings imply that overweight/obesity could create
a false positive screening cut-off level of PSA as a screening
test for PCa. We suggest interpretation of PSA levels with
clinical findings and other diagnostic methods such as his-
topathology, DRE and imaging studies.
5. Conclusion
Our study demonstrated that in a sample population of
predominantly native African men, there was a higher
likelihood of overweight/obese patients of having higher
PSA level; however, this association was washed off in a
logistic regression analysis. Additional studies are needed
to further clarify the links between BMI and PSA and to
determine whether weight reduction could lead to
improved level of serum PSA.
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